About this trial
Determination of the sites from which the histopathological samples in surgically removed lesions are collected is still done by eye by a pathologist. As radiological determination of regions of interest has already proven useful in in vivo use cases, the implementation of sampling of ex vivo lesions with the help of radiological imaging suggests great potential. By developing and implementing mold printing processes, these molds have the potential to vastly improve the accuracy and consistency of histopathological sampling and collection of tissue samples from different regions of tumor, leading to improved characterization, more individualized treatments, and eventually better survival.
Eligibility criteria
Qualifiers
be willing and able to give informed consent and give their written consent for the participation in the study (in case of a child (<15-year-old), the consent is collected in an age-appropriate manner from the study candidate and their legal guardian(s))
have a malignant or likely malignant tumor/tumors and undergo a surgical operation.
Disqualifiers
lack the capacity to provide informed consent (if a legal guardian objects to the participation of their child (<15-year-old), the child is not eligible);
be at risk of having their standard of care treatment jeopardized by the study, in the opinion of their physician.
Trial design
Treatments tested in this trial
- 3D-printed tumor mold for tissue sampling
Treatment groups
Sponsors and collaborators
Tampere University Hospital
Lead sponsor
Tampere University
Collaborator
Kuopio University Hospital
Collaborator
University of Eastern Finland
Collaborator